Table 9.
GRADE Evidence Profile comparing once-daily mesalamine with multiple-times daily mesalamine for induction and maintenance of remission in patients with mild-moderate ulcerative colitis
| ONCE-DAILY COMPARED TO MULTIPLE-TIMES DAILY MESALAMINE FOR MILD-MODERATE ULCERATIVE COLITIS | ||||||
|---|---|---|---|---|---|---|
| Outcomes | Anticipated absolute effects* (95% CI) | Relative effect (95% CI) | Absolute effect | № of participants (studies) | Quality of the evidence (GRADE) | |
| Risk with multiple-times daily mesalamine | Risk with once-daily mesalamine | |||||
| Failure to induce remission | 477 per 1,000 | 458 per 1,000 (405 to 515) | RR 0.96 (0.85 to 1.08) | 19 fewer per 1,000 (from 38 more to 72 fewer) | 944 (4 RCTs) | ⨁⨁⨁◯1 MODERATE |
| Failure to maintain remission | 281 per 1,000 | 269 per 1,000 (238 to 300) | RR 0.96 (0.85 to 1.07) | 11 fewer per 1,000 (from 20 more to 42 fewer) | 4465 (11 RCTs) | ⨁⨁⨁◯1 MODERATE |
|
GRADE Working Group grades of evidence High quality: We are very confident that the true effect lies close to that of the estimate of the effect Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect | ||||||
1
Rated down for imprecision